Market Data
Market Cap₹304.37 Cr.
52W High₹104.8
Current Price₹84.19
52W Low₹44.49
Down from 52W High19.7 %
Face Value₹10
Performance
ROCE-5.58 %
ROE-9.63 %
EPS (TTM)₹0.57
EPS Prev Qtr₹-2.1
EPS Last Year₹-0.94
EBITDA Qtr₹2.54 Cr.
Book Value₹26
Financial Health
Debt/Equity0.52
Debt/Profit-5.16
Total Assets₹174.536 Cr.
Promoter Holding58.45 %
Earning Power-6.39 %
Valuation
Industry P/E33.81
Price to Book3.29
Price to Sales2.21
Key Metrics
Face Value
₹10
About Lyka Labs Ltd
Healthcare · Pharmaceuticals
Lyka Labs Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹304.37 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a promoter holding of 58.45%, indicating strong control and alignment of interests.
- The company maintains a moderate debt-to-equity ratio of 0.52, suggesting manageable leverage levels.
Weaknesses
- The company is currently operating at a loss with a net profit of ₹-9.38 Cr.
- It has a negative P/E ratio of -33.38, reflecting that it is not profitable and trading at a discount.
- The Return on Capital Employed (ROCE) is negative at -5.58%, indicating inefficient use of capital.
- The Return on Equity (ROE) is negative at -10.15%, showing poor profitability relative to shareholder equity.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 36.66 | 30.73 | 28.03 | 42.31 |
| ↳ QoQ Growth | - | -16.2% | -8.8% | +50.9% |
| Expenses | 41.35 | 31.23 | 36.53 | 39.77 |
| Operating Profit | -4.69 | -0.51 | -8.5 | 2.54 |
| OPM % | -12.79% | -1.66% | -30.32% | 6% |
| Other Income | 1.09 | 1.16 | 0.61 | 0.42 |
| Interest | 0.79 | 0.82 | 0.7 | 1.01 |
| Depreciation | 2.15 | 2.15 | 2.04 | 2.01 |
| EBITDA | -2.54 | 1.64 | -6.46 | 4.55 |
| EBITDA Margin % | -6.93% | 5.34% | -23.05% | 10.75% |
| Profit Before Tax | -4.38 | -0.16 | -8.59 | 1.95 |
| Tax % | 26.71% | 6.25% | 6.05% | -5.13% |
| Net Profit | -3.21 | -0.15 | -8.07 | 2.05 |
| ↳ QoQ Growth | - | +95.3% | -5280.0% | +125.4% |
| EPS | -0.94 | 0 | -2.1 | 0.57 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 35.69 | 35.69 |
| Reserves | 67.86 | 56.7035 |
| Borrowings | 39.19 | 48.36 |
| Other Liabilities | 33.47 | 33.78 |
| Total Liabilities | 176.21 | 174.5364 |
| Fixed Assets | 76.9 | 87.1334 |
| CWIP | 0.2 | 1.8566 |
| Investments | 0.04 | 0.03 |
| Other Assets | 99.07 | 85.52 |
| Total Assets | 176.21 | 174.5364 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 5.2428 |
| Cash from Investing Activity | -9.4138 |
| Cash from Financing Activity | 4.1861 |
| Net Cash Flow | 0.0151 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 58.16% | 58.16% | 58.16% | 58.45% |
| FIIs % | 0.18% | 0.17% | 0.29% | 0.17% |
| DIIs % | 0.67% | 0.67% | 0.67% | 0.66% |
| Public % | 31.52% | 31.42% | 31.06% | 31.18% |
| No. of Shareholders | 27,743 | 27,155 | 26,727 | 29,369 |
Major Shareholders (>1%)
- Ipca Laboratories LimitedPromoter and Promoter Group40.45%
- Kunal Narendra GandhiPromoter and Promoter Group10.03%
- Nehal Narendra GandhiPromoter and Promoter Group3.60%
- Enai Trading And Investment Pvt. LtdPromoter and Promoter Group3.04%
As of 2026-06-30View all shareholders →